In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at ... of the fact that Wegovy and Ozempic, along with their oral sibling ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Please provide your email address to receive an email when new articles are posted on . Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss ...

Semaglutide 7.2 mg achieved 20.7% weight loss at 72 weeks versus 17.5% for 2.4 mg and 2.4% for placebo in the STEP UP trial. 33.2% of participants on 7.2 mg lost ≥25% body weight compared to 16. ...

That compared with 15.6% weight loss among people taking the currently approved 2.4-mg dose, and 3.9% among people taking placebo, Novo said Friday.

In a 72-week study, a 7.2-mg dose of Wegovy led patients with obesity to lose 18.7% of their weight, when looking at all participants regardless of how well they adhered to treatment. That ...

In the race to find Ozempic ... treat type 2 diabetes, sold under the brand name Rybelsus, and they're trialing a high-dose version of that pill that could be approved for weight loss.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The maintenance dose of Ozempic for weight loss is usually 1.0 mg per week. Some individuals may require an increase to 2.0 mg if recommended by their healthcare provider. Always adhere to the ...

Topline findings from the 72-week STEP UP trial (NCT05646706) show that semaglutide at a dose of 7.2 mg produced superior weight loss compared to semaglutide ... in both long-acting injectable (Wegovy ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The maximum semaglutide dose for weight loss is 2.4 milligrams (mg) per week ... The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in recent years.